Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Sutro_Biopharma,_Inc._acquired_by_a_larger_entity
|
| gptkbp:advertising |
targeted therapies
growth and innovation |
| gptkbp:businessModel |
biotech innovation
|
| gptkbp:CEO |
gptkb:Bill_Newell
|
| gptkbp:clinicalTrials |
ongoing
Phase 1 immuno-oncology multiple candidates cancer therapies emphasized multiple sites promising results |
| gptkbp:collaborations |
ongoing
academic institutions AbbVie various institutions global partners |
| gptkbp:community_engagement |
active
|
| gptkbp:community_service |
defined
|
| gptkbp:employees |
approximately 100
|
| gptkbp:enrollment |
diverse
|
| gptkbp:financialPerformance |
growing
|
| gptkbp:focus |
therapeutics
|
| gptkbp:founded |
2003
|
| gptkbp:founder |
gptkb:Bill_Newell
|
| gptkbp:funding |
public offerings
grants and investments |
| gptkbp:future_plans |
clinical stage
|
| gptkbp:governance |
strong
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sutro Biopharma, Inc.
|
| gptkbp:investmentFocus |
active
significant various venture capital firms |
| gptkbp:market |
expanding
biopharmaceuticals |
| gptkbp:mission |
develop novel therapies
|
| gptkbp:partnerships |
gptkb:Merck
various pharmaceutical companies Celgene |
| gptkbp:patentCitation |
patents
|
| gptkbp:platforms |
cell-free protein synthesis
|
| gptkbp:products |
multiple
|
| gptkbp:publications |
numerous
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
ongoing |
| gptkbp:research |
various projects
|
| gptkbp:research_areas |
oncology
various types |
| gptkbp:research_focus |
protein therapeutics
|
| gptkbp:sells |
STRO
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:supplyChain |
STRO-001
|
| gptkbp:sustainability_initiatives |
ongoing
|
| gptkbp:team |
experienced professionals
|
| gptkbp:technology |
continuous
XpressCF |
| gptkbp:vision |
transform patient care
|
| gptkbp:website |
www.sutrobio.com
|